Opportunity to generate competition in the biologics space with 600 biosimilar approvals covering over 10 therapeutic areas
Source of data: IGBA membership, Swissmedic and HSA Singapore
2 November 2022
International Generic and Biosimilar medicines Association (IGBA)
Access to Medicine Foundationaccesstomedicinefoundation.org
Argentinian Generic and BiosimAlazharanufacturers Associationwww.cilfa.org.ar
Association of Generic and Biosimilar Drug Manufacturers for the Republic of Serbia and the Republic of Montenegrogenezis.org
Bangladesh Association of Pharmaceutical Industries (BAPI)www.bapi-bd.com
Biocon Biologics Limitedwww.biocon.com
BioSim - Asociación Española de Medicamentos Biosimilareswww.biosim.es
Biosimilars Council, a division of the Association for Accessible Medicinesbiosimilarscouncil.org
Biosimilar Medicines Group, a Medicines for Europe sector groupwww.medicinesforeurope.com/biosimilar-medicines
Biosimilars Review & Report (BR&R)biosimilarsrr.com
British Biosimilars Association (BBA)britishbiosimilars.co.uk
Canadian Biosimilars Forumwww.canadianbiosimilarsforum.ca
Centro de Pensamiento Medicamentos, Información y Poder - Universidad Nacional de Colombiapensamiento.unal.edu.co
GBMA | Generic and Biosimilar Medicines Association Australiawww.gbma.com.au/biosimilars
GENAS - Association for generic and biosimilar medicineswww.genas.sk
Generic & Biosimilar Medicines Southern Africagbmsa.org
Generics and Biosimilars Initiative (GaBI)www.gabionline.net
Informa Pharma Intelligence Awards 2022pharmaintelligence.informa.com/events/awards/japan-awards-2022/
Health Care Solutionwww.hcspharma.com
Indian Pharmaceutical Allianceipa-india.org
Institut Pasteur Marocwww.pasteur.ma
JAPM | Jordanian Association of Pharmaceutical Manufacturerswww.japm.com
JGA | Japan Generic Medicines Associationwww.jga.gr.jp
Malaysian Organisation of Pharmaceutical Industries (MOPI)mopi.org.my
PPD by Thermo Fisherwww.thermofisher.com
PROGENÉRICOS | Brazilian Association of Generic and Biosimilar Medicines Industrieswww.progenericos.org.br
Pro Salud Chile A.G.prosaludchile.cl
Samsung Bioepis (US)www.samsungbioepis.com
The Center for Biosimilarswww.centerforbiosimilars.com
TGPA | Taiwan Generic Pharmaceutical Associationwww.tgpa.org.tw/
Dr María José Cuadrado is a Senior Consultant and Directors of the Rheumatology Service of the Clinical Universidad de Navarra in Madrid, Spain.
Dr Cuadrado graduated in Medicine and Surgery from the University of Malaga, Spain in 1979. And obtained a PhD from the University of Córdoba, Spain in 1990. Her clinical and basic research has been focused on systemic autoimmune disease Lupus erythematosus, antiphospholipid syndrome and pregnancy in patients with rheumatic diseases. Dr Cuadrado has spent her career divided between hospitals in Spain and in London, England.
Dr. Hillel P. Cohen PhD is Executive Director of Scientific Affairs at Sandoz Inc; a division of Novartis, helping explain the principles of biosimilars and biosimilar policies to the healthcare community, patient advocacy groups, and other stakeholders. He has published and given presentations in the areas of biosimilar education, switching, interchangeability, totality-of-evidence and naming and safety.
Steven Selde, JS, is the Director of the Biosimilars Council, a division of the Association of Accessible Medicines. In this role, he works to identify issues affecting Biosimilars Council members’ interests and develop and implement advocacy strategies and tactics that effectively support those interests. In addition to these policy-related efforts, he works to increase the public’s understanding about these lifesaving medicines and is a member of the IGBA Global Biosimilars Week Task Force.
Published 26 July 2022. Downloaded from the publisher’s website close to 7000 times in the first three months since publication Cohen, H.P., Hachaichi, S., Bodenmueller, W. et al. Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies. BioDrugs 36, 625–637 (2022). https://doi.org/10.1007/s40259-022-00546-6
Published March 2018. Downloaded from the publisher’s website over 29,000 times. Over 130 direct citations in other peer-reviewed journals. Cohen, H.P., Blauvelt, A., Rifkin, R.M. et al. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. Drugs 78, 463–478 (2018). https://doi.org/10.1007/s40265-018-0881-y
Born in London, Cary Adams has a BSc Honours degree in Economics, Computing and Statistics from the University of Bath, United Kingdom and a Masters degree (with Distinction) in Business Administration. He is a Harvard Business School Alumni having attended the School’s Executive General Management programme in 2003.In 2009, Cary made a career change, moving from the management of international businesses in the banking sector to become CEO of UICC based in Geneva.UICC unites the cancer community to reduce the global cancer burden, to promote greater equity, and to integrate cancer control into the world health and development agenda. Its rapidly increasingmembership base of over 900 organisations in more than 150 countries features the world’s major cancer societies, ministries of health and patient groups and includes influential policy makers, researchers and experts in cancer prevention and control. UICC also boasts more than 50 strategic partners.Cary and his team focus on global advocacy, convening the cancer community (through World Cancer Day, the World Cancer Congress and the World Cancer Leaders’ Summit) and running significant global capacity building projects that address global cancer issues.Cary also served two terms as Chair of the NCD Alliance, a coalition of around 2,000 organisations working on non-communicable diseases, which include cancer, diabetes, heart, respiratory, mental and neurological diseases.In 2014 he was awarded an Honorary Doctorate in International Relations from the University for Business and International Studies in Geneva, and in 2015 an Honorary Doctorate in Health from Bath University in the UK. In May 2015, Cary was awarded ‘CEO of the year’ at the International and European Association conference organised by the Associations Network.
Suzette Kox is the first Secretary General of the International Generic and Biosimilar Medicines Association. She was nominated in January 2019, after 17 years in various functions at Medicines for Europe. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. Before joining the generic medicines industry in 1992, Suzette followed a hospital and retail pharmacy career. Along with a degree in pharmacy (Paris), she holds a postgraduate diploma in anatomy-pathology (Cochin Port Royal, Paris).